产品名称
氯贝丁酯, European Pharmacopoeia (EP) Reference Standard
InChI
1S/C12H15ClO3/c1-4-15-11(14)12(2,3)16-10-7-5-9(13)6-8-10/h5-8H,4H2,1-3H3
SMILES string
CCOC(=O)C(C)(C)Oc1ccc(Cl)cc1
InChI key
KNHUKKLJHYUCFP-UHFFFAOYSA-N
grade
pharmaceutical primary standard
API family
clofibrate
manufacturer/tradename
EDQM
technique(s)
HPLC: suitable
gas chromatography (GC): suitable
application(s)
pharmaceutical (small molecule)
format
neat
storage temp.
2-8°C
Gene Information
human ... PPARA(5465)
正在寻找类似产品? 访问 产品对比指南
Application
Clofibrate EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Other Notes
Sales restrictions may apply.
Packaging
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
signalword
Danger
hcodes
Hazard Classifications
Acute Tox. 4 Oral - Eye Dam. 1 - Skin Irrit. 2 - STOT SE 3
target_organs
Respiratory system
存储类别
10 - Combustible liquids
wgk
WGK 3
flash_point_f
235.4 °F - closed cup
flash_point_c
113 °C - closed cup
[Currently used therapeutic agents for arteriosclerosis--with special reference ro a protein anabolic hormone, clofibrate (C.P.I.B.)].
T Yasugi et al.
Nihon rinsho. Japanese journal of clinical medicine, 28(5), 1470-1474 (1970-05-01)
[The treatment of essential hyperlipidemia with clofibrate].
W Reuter et al.
Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete, 24(1), Suppl:184-Suppl:187 (1969-01-01)
Hypolipidemic effect of clofibrate and fatty acid oxidation in peroxisomes.
Nutrition reviews, 35(4), 74-75 (1977-04-01)
Tao Xiong et al.
Indian pediatrics, 49(1), 35-41 (2012-02-10)
To evaluate the effect of clofibrate for unconjugated hyperbilirubinemia in neonates. A systematic review with meta-analysis of randomized controlled trials or quasi-randomized controlled trials was conducted to evaluate the clofibrate treatment in neonates with unconjugated hyperbilirubinemia. We followed the guidelines
[Fibrates: mechanism of action, effect on levels of lipids and lipoproteins, risk of coronary events. Part 1. Clofibrate, gemfibrosil, besafibrate].
L M Dobordzhginidze et al.
Kardiologiia, 44(2), 96-103 (2004-05-06)
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持